Author:
Skerlev Mihael,Čulav-Košćak Ivana,Ljubojević Hadžavdić Suzana,Sirotković-Skerlev Maja
Publisher
Springer Berlin Heidelberg
Reference59 articles.
1. Ahmed I, Berth-Jones J. Imiquimod: a novel treatment for lentigo maligna. Br J Dermatol. 2000;143:843–5.
2. Ahn MY, Kwon SM, Cheong HH, et al. Toll-like receptor 7 agonist, imiquimod, inhibits oral squamous carcinoma cells through apoptosis and necrosis. J Oral Pathol Med. 2012;41(7):540–6.
3. Aldara. Package insert. Revised 03/2013. Available from:
http://www.almp.hr/upl/lijekovi/PIL/UP-I-530-09-10-01-451.pdf
.
4. Arevalo I, Tulliano G, Quispe A, et al. Role of imiquimod and parenteral meglumine antimoniate in the initial treatment of cutaneous leishmaniasis. Clin Infect Dis. 2007;44:1549–4.
5. Babel N, Eibl N, Ulrich C, et al. Development of Kaposi’s sarcoma under sirolimus-based immunosuppression and successful treatment with imiquimod. Transp Infect Dis. 2008;10:59–62.